BCG, A Magic Potion
Missions
Respecting its humanitarian mission to "eradicate TB globally," and enjoying a high yield cultivation technology "High Yield" for mycobacteria (BCG), Rabvaccine is ready to transfer its know-how in industrial production of BCG vaccine adapting to the economic, geographic and trade of each country.
Studies
SAS RABVACCINE offers models of anti-cancer screenings, anti-asthmatic and anti-inflammatory in mice and guinea pigs. Until now, the company has completed 37 pharmaceutical research projects.
A) Studies on mucosal routes of administration and mucosal immunity against Mycobacteria
Similar functional activity of dendritic cells recruited to the mesenteric lymph nodes of newborn and adult mice after the rectal delivery of Mycobacterium bovis BCG. Abolhassani M, Lagranderie M, Caminshi I, Romain F, Balazuc AM, Wagner MC, Tanguy M, Fiette L, Sobhani I, Milon G, Marchal G. Microbes Infect. 2006 Aug; 8(9-10):2341-51.
Development of mixed Th1/Th2 type immune response and protection against Mycobacterium tuberculosis after rectal or subcutaneous immunization of newborn and adult mice with Mycobacterium bovis BCG. Lagranderie M, Balazuc AM, Abolhassani M, Chavarot P, Nahori MA, Thouron F, Milon G, Marchal G. Scand J Immunol. 2002 Mar;55(3):293-303.
Mycobacterium bovis BCG induces similar immune responses and protection by rectal and parenteral immunization routes. Abolhassani M, Lagranderie M, Chavarot P, Balazuc AM, Marchal G. Infect Immun. 2000 Oct;68(10):5657-62.
B) BCG against inflammatory diseases (Alzheimer's disease, Crohn Disease/ Disease Chronic Inflammatory Bowel disease (IBD) and Atherosclerosis
Control Of Intestinal Inflammatory Syndromes With A Preparation Of Killed Or Non Infectious Bacteria https://patentimages.storage.googleapis.com/73/00/6a/36a36397cc4dea/CA2531261A1.pdf
Mycobacterium bovis Bacillus Calmette-Guérin killed by extended freeze-drying reduces colitis in mice. Lagranderie M, Kluge C, Kiefer-Biasizzo H, Abolhassani M, Nahori MA, Fitting C, Huerre M, Bandeira A, Bercovier H, Marchal G. Gastroenterology. 2011 Aug;141(2):642-52, 652.e1-4.
Mycobacterium bovis bacillus Calmette-Guérin killed by extended freeze-drying targets plasmacytoid dendritic cells to regulate lung inflammation. Lagranderie M, Abolhassani M, Vanoirbeek JA, Lima C, Balazuc A, Vargaftig BB, Marchal G. J Immunol. 2010 Jan 15;184(2):1062-70.
Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models. Lagranderie M, Abolhassani M, Vanoirbeek J, Lefort J, Nahori MA, Lapa E Silva JR, Huerre M, Vargaftig B, Marchal G. J Allergy Clin Immunol. 2008 Feb;121(2):471-8.
Marchal G. and Abolhassani M. US Patent N° 20090280146 - USPTO Applicaton : #20090280146 - Class 4242481 (USPTO) Control of intestinal inflammatory syndromes with a preparation of killed or noninfectious bacteria.
Marchal G., Lagranderie M., Abolhassani M. et Bercovier H. 2005 Y/Réf: DI n° 2004-110 and N/Réf 000466-0087: "Diminution des syndromes inflammatoires du colon par l’EFD", enregistrée en New Canadian Patent Application au 21 décembre 2005 avec le titre : "Control of intestinal inflammatory syndromes with a preparation of killed or non-infectious bacteria ".
Marchal G., Lagranderie M., Abolhassani M., Bercovier H. and Maron A. 2008 Y/Réf: DI n° 2008-23 and O/Reference : 000466-0162 : Registered in 14 April 2008 under the title: "Control of diseases associated with decrease of T-Regulatory cells with a preparation of extended freeze-dried killed bacteria ".
C) Recombinant BCG intravesical against invasive bladder cancer (agressive)
Recombinant Mycobacterium Strain Expressing A Mycobacterial Fap Protein Under The Control Of A Promoter Active Under Hypoxia And Its Application For Cancer Therapy; https://patentimages.storage.googleapis.com
/0b/01/8e/3a3c5817c68c3b/WO2008012693A2.pdf
Marchal G. and Abolhassani M. US Patent N° 20090304637 - USPTO Applicaton #: #20090304637 - Class: 424932 (USPTO) Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy.
Marchal G. and Abolhassani M. 2006 Service des Brevets et Inventions, Institut Pasteur, Déclaration d’invention - Réf : DI n° 2006-06 "BCG overexpressing Apa for the treatment of bladder cancer".
D) BCG to control mortality Covid-19
The efficacy of BCG in the control of respiratory inflammation and the mortality rate of pulmonary infections due to COVID-19, has been validated by more than 120 articles and 2 clinical trials.
Our company, Rabvaccine, is currently developing a new formulation for intradermal administration of BCG in adults as "protection against COVID".
